Dopo l'orario di chiusura: 6.82

Amneal Pharmaceuticals Inc (AMRX)

Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie

Amneal Pharmaceuticals Inc (AMRX)

Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 15.4% in April - Defense World

Amneal Pharmaceuticals (NASDAQ:AMRX) Hits New 1-Year High at $6.95 - MarketBeat

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat

Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for - Yahoo Singapore News

Is a Surprise Coming for Amneal (AMRX) This Earnings Season? - Yahoo Movies Canada

Amneal Pharmaceuticals (NYSE:AMRX) shareholders have endured a 88% loss from investing in the stock five years ago - Yahoo Canada Shine On

Amneal Pharmaceuticals (AMRX) Stock Forecast and Price Target 2024 - MarketBeat

Why Is Generic Drug-Focused Amneal Pharmaceuticals Stock Trading Lower Friday? - MSN

Amneal (AMRX) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Singapore News

LSV Asset Management Lowers Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - MarketBeat

Amneal Pharmaceuticals (AMRX) Surges: Stock Moves 8.6% Higher - Yahoo New Zealand News

The Goldman Sachs Group Boosts Amneal Pharmaceuticals (NASDAQ:AMRX) Price Target to $8.00 - Defense World

Xeris Pharmaceuticals (XERS) in Focus: Stock Moves 6.8% Higher - Yahoo News UK

Assessing Amneal Pharmaceuticals: Insights From 4 Financial Analysts

Assessing Amneal Pharmaceuticals: Insights From 4 Financial Analysts - Amneal Pharmaceuticals (NASDAQ:AMR - Benzinga

Amneal (AMRX) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Movies Canada

Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 1-Year High at $6.90 - Defense World

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $7.31 Consensus Price Target from Brokerages - Defense World

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2024 Earnings Call Transcript - Insider Monkey

Amneal Pharmaceuticals First Quarter 2024 Earnings: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023) - Simply Wall St

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2024 Earnings Call Transcript - Yahoo Finance

Drugmaker Amneal agrees to $270 million U.S. opioid settlement - MSN

Amneal stock climbs on Q1 report, opioid settlement update (NASDAQ:AMRX) - Seeking Alpha

Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall

Amneal (AMRX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength? - MSN

Amneal: Q1 Earnings Snapshot - Press of Atlantic City

Amneal shares up nearly 4% on better-than-expected Q1 results - Investing.com India

Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates

Amneal Reports First Quarter 2024 Financial Results - Business Wire

Generic Drugmaker Amneal Announces Over $270M In US Opioid Lawsuit Settlement - Amneal Pharmaceuticals (N - Benzinga

ACAD: Buy Alert: 3 Pharma Stocks Under $20 to Invest in Now - StockNews.com

Mackenzie Financial Corp Has $110000 Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Drug Company Can't Escape Texas Counties' Opioid MDL - Law360

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - MarketBeat

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Update - Defense World

Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength?

Strength Seen in Amneal (AMRX): Can Its 12.0% Jump Turn into More Strength? - Zacks Investment Research

FDA approves Amneal's generic version of OTC Narcan (NASDAQ:AMRX) - Seeking Alpha

Marquis Who's Who Honors Ravi D. Patel for Expertise in the Pharmaceutical Industry - 24-7 Press Release

Naresh Gaur, Sr VP - Manufacturing Operations, Amneal Pharma - Express Pharma

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine - Business Wire

Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price - Simply Wall St

Amneal to Report First Quarter 2024 Results on May 3, 2024 - Business Wire

Amneal to Report First Quarter 2024 Results on May 3, 2024 - Yahoo Finance UK

Bausch (BHC) Starts Litigation Against Amneal for Xifaxan

Bausch Health files patent lawsuit against Amneal Pharma for its liver disease drug - The Financial Express

Bausch Health sues Amneal over Xifaxan generic (NASDAQ:AMRX) - Seeking Alpha

Bausch Health Sues Amneal Over IBS Treatment Patent - MarketWatch

Amneal to Ring the Nasdaq Closing Bell on April 2, 2024 - Business Wire

Simile a AMRX